Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M

PUMA BIOTECHNOLOGY, INC.

2023-FY EPS reported $0.45 revenue$235,637,000

Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.
Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.
Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.
Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

PUMA BIOTECHNOLOGY, INC. reported financial results for fourth quarter and year ended December 31, 2023.

Period: fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-006099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.